We are live on ! Find out more
RUBY

Rubius Therapeutics

Delisted

RUBY was delisted on the 6th of March, 2023.

75 hedge funds and large institutions have $632M invested in Rubius Therapeutics in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

454% more capital inflows, than outflows

Capital inflows: $31M | Capital outflows: $5.6M

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

114% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 14

9% more funds holding

Funds holding: 69 → 75 (+6)

3.08% more ownership

Funds ownership: 97.96% → 101.04% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3% less call options, than puts

Call options by funds: $758K | Put options by funds: $785K

Holders
75
Holders Change
+6
Holders Change %
+8.7%
% of All Funds
1.64%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
10
Increased
30
Reduced
14
Closed
4
Calls
$758​K
Puts
$785​K
Net Calls
-⁠$27​K
Net Calls Change
-⁠$27​K

RUBY Hedge Fund Activity: Q3 2019 in Review

75 of the 4,577 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics (RUBY) for Q3 2019, worth a combined $632M — down 49% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new RUBY positions and 4 closed out — a net gain of 6 holders — while 30 added to existing stakes and 14 trimmed.

The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $4.66M. The largest seller was EcoR1 Capital, cutting an estimated $2.37M.

  • 75 institutional investors held Rubius Therapeutics (RUBY) as of Q3 2019, up from 69 in Q2 2019.
  • Funds reported $632M of Rubius Therapeutics stock for Q3 2019, down 49% quarter-over-quarter.
  • 10 funds opened new Rubius Therapeutics positions in Q3 2019 and 4 closed out, a net change of +6 holders.
  • The largest Rubius Therapeutics buyer in Q3 2019 was Alkeon Capital Management, an estimated $4.66M added.
  • The largest Rubius Therapeutics seller in Q3 2019 was EcoR1 Capital, an estimated $2.37M sold.

Based on aggregated 13F filings for Q3 2019.